Atara Biotherapeutics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report; it does not provide a separate Q4 income statement. Atara is a clinical-stage cell-therapy company. Its lead therapy, Ebvallo (tab-cel), received European Commission authorization in December 2022; the company reported no revenue from commercial product sales in 2022.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| License and collaboration revenue | $63.6 million | $20.3 million |
| Research and development expense | $272.5 million | $282.0 million |
| General and administrative expense | $71.6 million | $78.8 million |
| Operating loss | $280.5 million | $340.5 million |
| Net loss | $228.3 million | $340.1 million |
| Net loss per share | $2.24 | $3.63 |
| Cash used in operating activities | $270.4 million | $220.5 million |
| Cash, cash equivalents and short-term investments at year-end | $242.8 million | $371.1 million |
- FY2022 revenue primarily reflected $61.8 million recognized following termination of the Bayer agreements; it is not evidence of commercial product sales. Revenue is expected to decline substantially after the Bayer termination.
- Net loss improved year over year, aided by a $50.2 million gain on the sale of the ATOM manufacturing facility. Operating cash use increased by $49.9 million.
- At December 31, 2022, current assets were $295.1 million and current liabilities were $78.9 million. Stockholders’ equity was $126.6 million. The filing reports no conventional borrowings; it records a $30.2 million liability related to the sale of future royalties, alongside lease obligations.
- The company received $94.8 million net from the ATOM asset sale and $30.6 million net from selling future royalty and milestone interests to HCRx. It also raised $22.0 million net through its at-the-market stock offering in 2022.
- No meaningful product gross margin is reported because there were no commercial product sales.
Material changes and business developments
- The EC authorized Ebvallo for relapsed or refractory EBV-positive post-transplant lymphoproliferative disease (PTLD) under exceptional circumstances. Pierre Fabre holds commercialization rights in Europe and selected emerging markets; launch activity in initial European countries was planned for Q1 2023. Atara retains rights in major markets including North America.
- Atara amended its Pierre Fabre agreement for an additional $30 million milestone in exchange for reduced royalties and supply-price markup. It also sold HCRx a portion of future Ebvallo royalties and milestones for $31.0 million; HCRx’s aggregate receipts are capped at 185%–250% of its investment, depending on timing.
- Atara sold the ATOM facility to FUJIFILM Diosynth Biotechnologies (FDB) in April 2022 and entered into a manufacturing and supply agreement. Atara remains jointly and severally liable on the assigned facility lease because landlord novation had not been obtained.
- Bayer terminated its collaboration; development rights for ATA2271 and ATA3271 reverted to Atara effective July 31, 2022. ATA3271 development was paused. Enrollment in the MSK-led ATA2271 study resumed after a temporary pause following a fatal serious adverse event in a higher-dose cohort.
- Atara reduced its workforce by approximately 20%. It recorded $6.0 million in restructuring charges and projected approximately $25 million of annualized operating-expense reductions by fiscal 2023.
Outlook, risks and contingencies
- Management expected year-end 2022 cash and investments, together with $40 million received in January 2023 for Pierre Fabre milestones, to fund planned operations into Q2 2024. The filing cautions that additional financing may be needed and may not be available on acceptable terms; it also identifies uncertainty about the company’s ability to continue as a going concern in future reporting periods.
- The U.S. tab-cel BLA pathway remains uncertain. FDA discussions addressed manufacturing comparability between pivotal-study and commercial product versions; an additional clinical study may be required. Atara expected to provide an update on a potential BLA submission in Q2 2023.
- Management expected the primary endpoint readout for ATA188’s Phase 2 EMBOLD study in an appropriate forum in October 2023. ATA3219 remained preclinical, with an IND filing planned for Q2 2023.
- Ebvallo’s EU authorization is subject to annual reassessment and post-marketing obligations. The filing cites clinical-development, manufacturing and supply, commercialization, reimbursement, competition, intellectual-property, and financing risks. EU demand forecasts indicated existing Ebvallo inventory was expected to cover commercial demand through year-end 2023.
- The HCRx agreement includes a potential $9 million payment by Atara if a specified Pierre Fabre milestone is not achieved by June 30, 2026. The company reported no material legal proceedings. Deloitte issued an unqualified audit opinion on the financial statements and internal controls; revenue recognition and accrued/prepaid R&D expenses were identified as critical audit matters.
Important facts for investors to verify
- Whether Pierre Fabre launched Ebvallo as planned, obtained pricing and reimbursement, and generated sales or milestone and royalty payments—and how the HCRx allocation affects Atara’s receipts.
- Current FDA alignment on tab-cel comparability, clinical-data requirements, and whether an additional study is needed before a U.S. BLA.
- Actual cash burn and financing runway compared with management’s Q2 2024 estimate, including the impact of pipeline spending and the remaining ATM capacity.
- Progress and outcomes for the EMBOLD endpoint, the planned ATA3219 IND, and safety monitoring in the ATA2271 study.
- Manufacturing capacity, commercial inventory sufficiency, and outstanding obligations under the FDB, CRL and assigned ATOM lease arrangements.